Form 4: Adaptive Biotechnologies CSO Executes Stock Sale
Statement of Changes in Beneficial Ownership
Chief Scientific Officer Harlan S. Robins sold 106,160 shares of Adaptive Biotechnologies common stock via a 10b5-1 plan.
Summary
- Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies, sold a total of 106,160 shares of common stock.
- The sales occurred on June 15, 2026 (100,000 shares at a weighted average of $17.37) and June 16, 2026 (6,160 shares at a weighted average of $18.01).
- Following these transactions, the reporting person retains beneficial ownership of 1,405,898 shares.
- The transactions were executed under a Rule 10b5-1 trading plan adopted on March 13, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-established 10b5-1 plan, which is a standard practice for executive financial planning.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without triggering concerns regarding non-public information.
Negatives
- The sale represents a reduction in the equity stake held by a key member of the executive leadership team.
Risks
- Insider selling can sometimes be perceived negatively by the market, potentially impacting short-term investor sentiment.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that insider selling by high-level executives, particularly C-suite officers, is a common occurrence for liquidity and diversification purposes and is typically viewed as neutral when executed via pre-planned 10b5-1 programs.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining compliance with SEC regulations.
Stakeholder Impact
- Shareholders should note the reduction in insider ownership, though the use of a 10b5-1 plan mitigates concerns regarding potential insider knowledge.
Key Dates
| Date | Description |
|---|---|
| 03/13/2026 | Date the Rule 10b5-1 trading plan was adopted. |
| 06/15/2026 | Date of the first reported stock sale transaction. |
| 06/16/2026 | Date of the second reported stock sale transaction. |
| 06/17/2026 | Date the Form 4 was signed and filed. |
Keywords
Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Chief Scientific Officer, Equity Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.